Aldeyra Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics' stock (ALDX) trades higher following an upgrade from Perform to Outperform by Oppenheimer, with a new price target of $10.
April 03, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aldeyra Therapeutics' stock received an upgrade from Oppenheimer from Perform to Outperform, alongside a new price target of $10, indicating a positive outlook.
The upgrade by Oppenheimer from Perform to Outperform signifies a strong vote of confidence in Aldeyra Therapeutics' future performance. The setting of a $10 price target further emphasizes the expected positive trajectory for the stock. Such analyst upgrades typically lead to increased investor interest and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100